BUD31

Across TCGA pan-cancer cohorts, BUD31 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BUD31 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BUD31 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BUD31 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where BUD31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.592	0.954	.001	37	view →
HNSC	DFS	Quartile	III,IV	0.714	0.968	.005	22	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
LSCC	DFS	Tertile	II,III,IV	0.891	0.548	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BUD31–CCRCC (DFS)

Open the CCRCC breakdown →